Back to Search
Start Over
Research Progress on the Weak Immune Response to the COVID-19 Vaccine in Patients with Type 2 Diabetes.
- Source :
-
Viral Immunology . Mar2024, Vol. 37 Issue 2, p79-88. 10p. - Publication Year :
- 2024
-
Abstract
- Coronavirus Disease 2019 (COVID-19) is generally susceptible to the population, highly infectious, rapidly transmitted, and highly fatal. There is a lack of specific drugs against the virus at present and vaccination is the most effective strategy to prevent infection. However, studies have found that some groups, particularly patients with diabetes, show varying degrees of weak immune reactivity to various COVID-19 vaccines, resulting in poor preventive efficacy against the novel coronavirus in patients with diabetes. Therefore, in this study, patients with type 2 diabetes mellitus (T2DM) who had weak immune response to the COVID-19 vaccine in recent years were analyzed. This article reviews the phenomenon, preliminary mechanism, and related factors affecting weak vaccine response in patients with T2DM, which is expected to help in the development of new vaccines for high-risk groups for COVID-19. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 08828245
- Volume :
- 37
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Viral Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 176101665
- Full Text :
- https://doi.org/10.1089/vim.2023.0097